Logo

AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients

Share this

AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients

Shots:

  • The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19- but not on assisted ventilation. The studies are being conducted in the US and outside the US including the EU- Japan and South America
  • The drug demonstrated the clinical improvement in peer-reviewed case series of 19 hospitalized patients with COVID-19 and hypoxia and/or inflammation. Results were published in Science Immunology
  • Calquence is a BTK inhibitor- act by inhibiting its activity and has received the US FDA approval for hematological malignancies

Click here to read full press release/ article 

Ref: AstraZeneca | Image: Twitter

 

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions